NP89
NOTICE OF ACCEPTANCE OF PARTIAL SEC. 8 & 9 EMAILED
20/12/2024
Voltar para busca
Dado oficial do USPTO
CELGENE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CELGENE
ST13
US500000076515116Classe
1, 5, 40, 41, 42
Pedido
76515116
Registro
2888517
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
14/01/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 40, 41, 42
Data de depósito
19/05/2003
Data de registro
28/09/2004
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/12/2024
Última transação
14/01/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Primeiro uso
31/12/1986
Primeiro uso no comércio
31/12/1986
Código do desenho
1
Tipo de titular
03
Localização do titular
Summit, NJ
Examinador
POWERS, ALEXANDER
Titulares e representantes
Titulares
C. C. (pessoa física)
C. C. (pessoa física)
Representantes
Marilyn F. Kelly Bristol-Myers Squibb Company
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 40Classe 41Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
biochemical catalysts for use in medical research; biological preparations for medical purposesfor use in the research of immunologicalinflammatory and neurological disorders; catalysts for use in the manufacture of pharmaceuticals; chemical preparationschemical reagents for scientific purposes; enzyme preparations for industrial purposes; enzymes for industrial purposes; proteins for industrial and human consumptionanimal proteinsgenetic testing reagents for scientific laboratory useDNA probes; chemical preparations used to protect crops in the agricultural and horticultural field; medicinal and biological preparations for medical laboratory usepreparations for the inhibition of gene expression working at DNAtranscriptionRNA or translation processesmodulation of immune system
Classe 5
biological preparations for medical purposesnamely for use in the treatment of immunologicalinflammatory and neurological disorders; pharmaceuticalsgenomic and biological agents for use in the fields of immunologicalinflammatory and neurological disorders for the identificationanalysispreventiondetectiondiagnosisprognosis and treatment; biological preparations for use in medicinal testsinoculationstreatment of diseasesimmunologicalinflammatory and neurological disorders and cancer; culture mediatissue culture media and bacteriogical culture media for medical use; medicinal and biological preparations for pharmaceutical and clinical usepreparations for the inhibition of gene expression working at DNAtranscriptionRNA or translation processesmodulation of immune system
Classe 40
manufacturing pharmaceutical products for others; custom synthesis of DNA to the order and specification of others; custom manufacturing servicesmanufacturing agrochemicals to the specification of others
Classe 41
educational classes and programs in the field of thalidomide and safety issues pertaining to thalidomidedistribution of written materials therewith
Classe 42
research in the fields of chemicals and pharmaceuticals; product safety testing in the fields of chemicals and pharmaceuticals; research and development of new products for others in the fields of chemicals and pharmaceuticals; providing clinical laboratory testing servicespharmacogenetic testspredictive medical testspersonalized medical testsgene sequencing-based tests and genotyping base on the assessmentdevelopment and application of genomic discoveries in the pharmaceuticalinformatics and clinical diagnostic industries; providing medical and pharmaceutical research information; scientific research services; design for others in the field of DNA-based assaysDNA sequencing protocolsimmunoassay and methods for drug discovery; scientific researchdevelopment of pharmaceuticals or diagnostic methods for others ; agrochemical product development for others
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
20/12/2024
9G8P
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
20/12/2024
8PRT
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
20/12/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
20/12/2024
E89R
TEAS SECTION 8 & 9 RECEIVED
11/09/2024
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
28/09/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/12/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/12/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
09/12/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/12/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/12/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/12/2022
NOSU
NOTICE OF SUIT
10/09/2020
NOSU
NOTICE OF SUIT
20/04/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
28/07/2015
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - MAILED
03/10/2013
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
02/10/2013
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
02/10/2013
9G8P
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
02/10/2013
8PRT
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
02/10/2013
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/10/2013
89AF
REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED
30/09/2013
E89R
TEAS SECTION 8 & 9 RECEIVED
30/09/2013
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
20/10/2009
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
20/10/2009
E815
TEAS SECTION 8 & 15 RECEIVED
02/10/2009
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
16/06/2005
R.PR
REGISTERED-PRINCIPAL REGISTER
28/09/2004
PUBO
PUBLISHED FOR OPPOSITION
06/07/2004
NPUB
NOTICE OF PUBLICATION
16/06/2004
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
30/04/2004
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
19/04/2004
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/02/2004
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/12/2003
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
19/12/2003
CNRT
NON-FINAL ACTION MAILED
12/12/2003
DOCK
ASSIGNED TO EXAMINER
29/11/2003
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CELGENE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.